Micosis sistémicas en pacientes con virus de la inmunodeficiencia humana/sida

Rodríguez-Cerdeira, Carmen; Arenas, Roberto; Moreno‐Coutiño, Gabriela; Vásquez, Elias; Fernández, Ramón; Chang, Patricia

doi:10.1016/j.ad.2012.06.017

Cited by 27 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have considered evaluating the efficacy of inhaled formulations in the prophylaxis of aspergillosis, since infection by Aspergillus sp. starts from inhalation of infectious spores (Rodríguez-Cerdeira et al, 2014 ). A lipid complex of AmB (Abelcet®) was administered as an aerosol for prophylaxis for pulmonary aspergillosis model in rats.…”

Section: Current Scenario Of Nanotechnology In the Treatment And Vaccmentioning

confidence: 99%

“…Endemic fungal infections are usually caused by dimorphic fungi, found in the soil or in animal feces. Host acquisition occurs by inhalation of infectious spores/infective propagules (Rodríguez-Cerdeira et al, 2014 ). In the case of endemic mycoses, immunocompetent individuals dwelling in endemic areas may develop severe disease following inhalation of fungal particles, associated or not to a competent immune response (Edwards et al, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Kischkel

Rossi

Santos

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates remain unacceptably high. Moreover, antifungal therapy is expensive, treatment periods can range from weeks to years, and toxicity is also a serious concern. In recent years, the increased number of immunocompromised individuals has contributed to the high global incidence of systemic fungal infections. Given the high morbidity and mortality rates, the complexity of treatment strategies, drug toxicity, and the worldwide burden of disease, there is a need for new and efficient therapeutic means to combat invasive mycoses. One promising avenue that is actively being pursued is nanotechnology, to develop new antifungal therapies and efficient vaccines, since it allows for a targeted delivery of drugs and antigens, which can reduce toxicity and treatment costs. The goal of this review is to discuss studies using nanoparticles to develop new therapeutic options, including vaccination methods, to combat systemic mycoses caused by Candida sp., Cryptococcus sp., Paracoccidioides sp., Histoplasma sp., Coccidioides sp., and Aspergillus sp., in addition to providing important information on the use of different types of nanoparticles, nanocarriers and their corresponding mechanisms of action.

show abstract

Section: Current Scenario Of Nanotechnology In the Treatment And Vaccmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Kischkel

Rossi

Santos

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…There are some risk factors associated with these infections, including immunocompromised patients undergoing invasive procedures [5], neonates [6], chemotherapy [7], burns [8], AIDS [9,10], among others [11,12]. In addition to these factors, socioeconomic conditions, geographical regions, and cultural habits are also important in the manifestation of these infections [13].…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles as a Tool for Broadening Antifungal Activities

Renzi

Campos

Miranda

et al. 2021

CMC

View full text Add to dashboard Cite

: The Fungal infections are diseases that are considered neglected although their infection rates have increased worldwide in the last decades. Thus, since the antifungal arsenal is restricted and many strains have shown resistance new therapeutic alternatives are necessary. Nanoparticles are considered important alternatives to promote drug delivery. In this sense, the objective of the present study was to evaluate the contributions of newly developed nanoparticles to the treatment of fungal infections. Studies have shown that nanoparticles generally improve the biopharmaceutical and pharmacokinetic characteristics of antifungals, which is reflected in a greater pharmacodynamic potential and lower toxicity, as well as the possibility of prolonged action. It also offers the proposition of new routes of administration. Nanotechnology is known to contribute to a new drug delivery system, not only for the control of infectious diseases, but for various other diseases as well. In recent years, several studies have emphasized its application in infectious diseases, presenting better alternatives for the treatment of fungal infections.

show abstract

“…Opportunistic fungal pneumonias (OFP) such as those caused by C. neoformans / C. gatii , P. jirovecii and H. capsulatum are clinically and radiologically similar to each other, and also to TB, which is usually the first clinical suspicion [ 6 , 7 ]. This fact delays the correct diagnosis with a great impact on the outcome of the patient [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Differential Diagnosis of Fungal Pneumonias vs. Tuberculosis in AIDS Patients by Using Two New Molecular Methods

Bernal‐Martínez

Herrera

Valero

et al. 2021

JoF

View full text Add to dashboard Cite

Opportunistic fungal pneumonias (OFP) are the main cause of death in AIDS patients worldwide. Diagnosis of these infections is often late as tuberculosis (TB) is frequently the first suspicion. In addition, diagnostic tools have limitations and are unavailable in disadvantaged regions. To perform the differential diagnosis of the main fungi causing OFP in AIDS patients (Histoplasma capsulatum, Cryptococcus neoformans/C. gattii and Pneumocystis jirovecii) vs. the Mycobacterium tuberculosis complex (MTBC), two new assays were developed: (i) a multiplex real-time PCR (MRT-PCR) and (ii) a simple and cost-effective method based on real-time PCR and the analysis of melting curves after amplification (MC-PCR). Both of the techniques were optimized and standardized “in vitro”, showing a suitable reproducibility (CV ranged between 1.84 and 3.81% and 1.41 and 4.83%, respectively), a 100% specificity and detection limits between 20 and 2 fg of genomic DNA per 20 µL of reaction. A validation study was performed by retrospectively using 42 clinical samples from 37 patients with proven fungal infection or TB, and 33 controls. The overall sensitivity for the MRT-PCR assay and the MC-PCR assay was 88% and 90.4%, respectively. Both techniques were fast, sensitive and reproducible, allowing for the detection of these pathogens and the performance of a differential diagnosis.

show abstract

Micosis sistémicas en pacientes con virus de la inmunodeficiencia humana/sida

Cited by 27 publications

References 60 publications

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Nanoparticles as a Tool for Broadening Antifungal Activities

Differential Diagnosis of Fungal Pneumonias vs. Tuberculosis in AIDS Patients by Using Two New Molecular Methods

Contact Info

Product

Resources

About